Acrodermatitis chronica atrophicans

L12_ACRODERMATITIS

acrodermatitis chronica atrophicans: An acrodermatitis characterized by a chronically progressive course, leading to widespread atrophy of the skin. It is a clinical manifestation of Lyme borreliosis.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L90.4
  • Hospital discharge: ICD-9 — 7018C
  • Hospital discharge: ICD-8 — 70190
  • Cause of death: ICD-10 — L90.4
  • Cause of death: ICD-9 — 7018C
  • Cause of death: ICD-8 — 70190

2 out of 7 registries used, show all original rules.

62

4. Check minimum number of events

None

62

5. Include endpoints

None

62

6. Filter based on genotype QC (FinnGen only)

60

Control definitions (FinnGen only)

Control exclude
L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L90
Name in latin
Acrodermatitis chronica atrophicans

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 334 248 84
Only index persons 309 234 75
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.00
Median age at first event (years)
Whole population 62.27 64.11 57.42
Only index persons 62.64 64.30 57.46

-FinnGen-

Key figures

All Female Male
Number of individuals 60 39 21
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 64.87 64.68 65.23

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
62
Matched controls
620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L90.4
ICD-10 Finland
Acrodermatitis chronica atrophicans
13423.3
84.4
61
*
L90.0
ICD-10 Finland
Lichen sclerosus et atrophicus
40.3
10.8
13
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
12.5
10.5
19
21
A69.2
ICD-10 Finland
Lyme disease
11.0
9.4
18
22
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
34.5
7.4
9
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.3
6.8
24
79
D07AD01
ATC
clobetasol; topical
4.7
6.3
18
50

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Case Management Agency
251B00000X (NUCC) [38004193]
Visit / Visit
4.2e-02 2.8e-01 5.6e-01 4.0e+00 7.7e-01 4.5e-02 —
73.33%/72.50% 71.67%/65.67% 40.00%/27.67% 36.67%/1.00% 46.67%/28.83% 68.97%/67.99% —/—
doxycycline; oral, parenteral
J01AA02 (ATC) [21602800]
ATC 5th / Drug
3.0e-01 1.5e+00 — 1.0e+50 3.6e+00 1.2e+00 —
20.00%/15.67% 16.67%/4.33% —/— 8.33%/0.00% 26.67%/1.00% 15.52%/5.02% —/—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X (NUCC) [38003841]
Physician Specialty / Provider
1.5e+00 3.0e+00 — 1.0e+50 — 3.5e+00 —
21.67%/5.67% 30.00%/2.00% —/— 63.33%/0.00% —/— 39.66%/1.90% —/—
Laboratory Visit
OMOP4822461 (Visit) [32036]
Visit / Visit
-2.3e-01 8.1e-02 1.4e+00 3.3e+00 8.1e-02 1.3e-01 —
41.67%/47.33% 46.67%/44.67% 40.00%/14.33% 18.33%/0.83% 15.00%/14.00% 46.55%/43.43% —/—
Dermatitis, unspecified
L30.9 (ICD10) [45572271]
ICD10 code / Condition
— 3.3e+00 — — — — —
—/— 18.33%/0.83% —/— —/— —/— —/— —/—
7818-8 (LOINC) [3008230]
Lab Test / Measurement
— 3.2e+00 — — — — —
—/— 16.67%/0.83% —/— —/— —/— —/— —/—
clobetasol
D07AD01 (ATC) [21602141]
ATC 5th / Drug
1.3e+00 2.7e+00 — — — 2.2e+00 —
10.00%/3.00% 11.67%/0.83% —/— —/— —/— 8.62%/1.04% —/—
7817-0 (LOINC) [3016888]
Lab Test / Measurement
— 2.7e+00 — — — — —
—/— 11.67%/0.83% —/— —/— —/— —/— —/—
53027-9 (LOINC) [3041942]
Lab Test / Measurement
— 2.7e+00 — — — -1.0e+50 —
—/— 11.67%/0.83% —/— —/— —/— 0.00%/1.38% —/—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
17
16.72
12.47
1.2
1.2
—
—
—
0
0
23
78
4.10
6.23
1.4
1.3
496.00
766.32
titre
—
5
19
11
18
7.17
4.86
1.1
1.2
0.27
0.23
g/l
0.64
11
18
11
18
7.17
4.86
1.1
1.2
1.22
1.14
g/l
0.29
11
18
24
110
2.93
3.83
1.6
1.3
31.18
38.55
iu/ml
—
6
44
10
24
4.76
3.37
1.1
1.2
—
—
—
0
0
36
223
2.46
2.99
2.4
2.0
—
—
—
0
0
37
245
2.27
2.48
3.5
3.6
6.38
6.23
ph
0.39
20
136
15
66
2.68
2.48
1.6
1.7
—
—
—
0
0
6
12
5.40
2.46
1.2
1.0
—
—
—
0
0
31
198
2.13
2.20
7.5
5.1
—
—
—
0
0
19
102
2.24
2.05
1.6
1.3
1.34
13.77
u/ml
—
5
36
25
152
2.08
1.97
4.5
3.7
80.44
93.61
%
1.43
25
152
7
28
2.69
1.50
11.7
9.7
26.29
25.51
mmol/l
—
7
28
10
46
2.40
1.49
9.1
8.1
1.15
1.44
mmol/l
—
10
46
27
189
1.76
1.31
8.1
6.7
—
—
—
0
0
35
267
1.71
1.23
8.4
10.6
0.00
0.00
e9/l
0.50
30
208
10
51
2.15
1.19
16.4
8.0
—
—
—
0
0
7
33
2.26
1.09
8.3
10.1
24.86
25.49
mmol/l
—
7
33
7
34
2.19
1.07
7.0
6.7
14.70
15.67
%
—
7
34
12
71
1.86
0.97
2.1
2.6
6.42
7.35
umol/l
0.17
12
65
24
178
1.57
0.87
2.9
2.9
—
—
estimate
—
0
0
0
25
0.00
0.81
0.0
3.8
—
1.28
—
0
25
12
76
1.72
0.78
2.2
3.4
1.67
1.67
%
0.00
12
67
5
23
2.27
0.78
1.0
3.7
—
—
—
0
0
33
270
1.48
0.73
2.4
2.2
81.04
94.05
pmol/l
0.73
14
133
14
96
1.59
0.69
1.8
2.0
—
—
—
0
0
17
123
1.53
0.67
3.2
4.7
—
—
—
0
0
12
80
1.62
0.65
9.1
6.5
105.83
104.35
mmol/l
0.72
12
80
15
106
1.55
0.65
2.5
3.0
0.77
0.81
mmol/l
0.76
15
101
29
236
1.43
0.64
3.6
4.0
11.71
89.84
e6/l
1.31
17
163
0
19
0.00
0.61
0.0
1.3
—
—
—
0
0
0
19
0.00
0.61
0.0
1.3
—
—
—
0
0
0
19
0.00
0.61
0.0
1.3
—
—
—
0
0
0
21
0.00
0.61
0.0
4.2
—
3.83
—
0
21
24
191
1.42
0.59
2.8
3.0
3.88
0.35
e6/l
0.45
16
137
6
37
1.69
0.57
7.5
10.9
93.67
94.10
%
—
6
37
6
40
1.55
0.53
7.5
10.2
1.40
1.41
%
—
6
40
6
40
1.55
0.53
7.5
10.1
0.45
0.71
%
—
6
40
23
186
1.38
0.51
8.2
3.9
7.39
7.40
ph
0.33
16
136
10
68
1.56
0.50
1.5
1.2
—
—
—
0
0
26
218
1.33
0.45
2.8
3.2
9.90
55.39
e6/l
1.69
18
164
22
180
1.34
0.44
3.8
2.4
67.59
57.05
u/l
0.34
22
165
12
158
0.70
0.44
1.4
1.5
—
—
—
0
0
8
58
1.43
0.44
1.1
1.2
—
—
—
0
0
5
32
1.61
0.43
6.8
2.4
0.80
0.64
%
—
5
32
5
32
1.61
0.43
6.8
2.4
0.98
1.23
%
—
5
32
0
15
0.00
0.42
0.0
7.0
—
—
—
0
0
0
15
0.00
0.42
0.0
7.5
—
1.06
—
0
15
37
329
1.31
0.41
8.8
6.6
12.16
11.03
umol/l
0.43
37
310
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
30
261
1.29
0.38
15.6
14.2
1.37
1.25
inr
0.43
23
220
6
42
1.47
0.37
1.0
1.2
—
—
—
0
0
6
42
1.47
0.37
1.3
2.0
—
—
—
0
0
56
574
0.75
0.34
26.5
18.5
139.73
139.81
mmol/l
0.08
56
563
7
54
1.33
0.32
1.1
1.3
—
—
—
0
0
8
63
1.31
0.29
7.9
8.2
108.88
121.22
g/l
—
8
63
57
550
1.45
0.28
6.2
6.4
2.77
2.67
mmol/l
0.35
52
512
9
71
1.31
0.27
1.9
1.4
—
—
—
0
0
22
191
1.24
0.27
3.0
3.2
—
—
—
0
0
56
538
1.42
0.26
5.3
5.5
5.71
5.94
mmol/l
1.03
51
495
12
146
0.78
0.25
4.8
6.1
3.45
2.20
ug/l
0.31
12
124
18
208
0.81
0.25
4.3
4.5
1.54
9.94
mg/mmol
1.85
11
136
23
258
0.83
0.24
3.2
2.7
—
—
estimate
—
0
0
25
224
1.19
0.22
2.4
4.5
23.00
24.18
ng/l
0.03
15
166
17
195
0.82
0.21
3.8
3.5
—
—
—
0
0
0
11
0.00
0.21
0.0
4.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
0.59
—
0
11
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
6.0
—
10.08
—
0
12
0
12
0.00
0.21
0.0
6.0
—
103.83
—
0
12
6
47
1.31
0.21
2.0
4.6
—
0.08
—
0
13
6
50
1.22
0.20
5.8
2.6
5.18
4.45
kpa
—
6
50
0
14
0.00
0.20
0.0
3.1
—
65.46
—
0
14
6
51
1.20
0.20
5.7
3.4
81.67
73.29
ng/l
—
6
43
15
129
1.21
0.19
1.6
1.8
0.75
2.00
mg/l
—
10
106
7
57
1.26
0.19
3.7
1.4
—
—
—
0
0
18
203
0.84
0.19
3.8
3.7
10.09
57.45
mg/l
1.97
11
136
8
67
1.22
0.17
7.1
8.2
1.16
1.78
mmol/l
—
8
57
8
68
1.20
0.17
8.0
8.0
11.34
11.66
kpa
—
8
68
8
68
1.20
0.17
8.1
8.0
5.31
5.04
kpa
—
8
68
56
544
1.30
0.16
5.7
5.4
4.70
4.62
mmol/l
0.23
50
505
54
523
1.25
0.15
4.9
4.5
1.10
1.26
mmol/l
1.25
48
475
47
451
1.17
0.15
13.4
8.6
76.98
80.89
u/l
0.27
47
421
5
43
1.18
0.10
2.6
4.9
1.24
1.22
mmol/l
—
5
37
5
44
1.15
0.10
1.8
4.5
—
1.14
—
0
14
5
45
1.12
0.10
1.8
4.9
—
0.00
—
0
12
5
48
1.05
0.09
1.8
4.7
—
0.73
—
0
15
6
58
1.04
0.08
2.7
1.9
—
0.00
estimate
—
0
14
7
65
1.09
0.08
8.1
8.2
95.56
95.48
%
—
7
65
56
546
1.26
0.08
22.9
15.7
24.36
21.36
mg/l
0.17
46
440
55
541
1.15
0.07
5.7
5.4
1.60
1.50
mmol/l
0.69
49
496
10
89
1.15
0.07
1.2
1.2
—
—
—
0
0
15
139
1.10
0.06
1.1
1.4
6.17
2.39
g/l
—
7
75
16
149
1.10
0.06
4.2
4.0
—
—
—
0
0
11
103
1.08
0.02
3.8
2.5
2.45
2.39
g/l
0.16
11
91
11
109
1.01
0.00
3.9
2.5
13.28
14.33
umol/l
0.18
11
100
17
174
0.97
0.00
2.5
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
16.10
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
10.4
—
0.64
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
22.6
—
5.67
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
2.36
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
0.34
—
0
5
0
9
0.00
-0.00
0.0
2.7
—
1.20
—
0
9
0
9
0.00
-0.00
0.0
2.7
—
108.00
—
0
9
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
32.50
—
0
8
0
8
0.00
-0.00
0.0
3.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
12.22
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
3.64
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
16.90
—
0
6
57
566
1.09
-0.00
15.7
14.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
7
72
0.97
-0.00
1.4
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
7.35
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.1
—
400.00
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
3.87
—
0
9
8
82
0.97
-0.00
1.9
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
6.94
—
0
5
5
57
0.87
-0.00
5.6
3.9
—
—
—
0
0
9
90
1.00
-0.00
1.6
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
1.35
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
32.88
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ACRODERMATITIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ACRODERMATITIS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: L12_ACRODERMATITIS – Acrodermatitis chronica atrophicans

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data